$XLRN News

Last published 4y ago

4y agoAGIO ARRY ATRA PTCT+1Qiming Venture Partners USA Announces $260 Million US Healthcare Fund III and Addition of New Partner, Isaac CiechanoverBusiness WireFund III will be invested in early-stage therapeutics and healthcare technology companies Qiming Venture Partners USA (Qiming US), a leading US healthcare investment firm, today announced the closing of its third fund, raising $260 million in an over
4y agoMRK XLRNMerck Completes Acquisition of Acceleron Pharma Inc.Business WireMerck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (NASDAQ:XLRN). "This is an important and strategic opportunity for our company to continue grow
4y agoMRK XLRNMerck Completes Tender Offer to Acquire Acceleron Pharma Inc.Business WireMerck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron Pharma
4y agoMRK XLRNAvoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate OfferBusiness WireBelieves Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company's Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Re
4y agoMRK XLRNMerck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.Business WireMerck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck's pending acquisition of Acceleron
5y agoMRK XLRNAvoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate OfferBusiness WireBelieves Now Is the Wrong Time to Cash out of Acceleron, Given Company's Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Sees Continuing as Standalone Entity as Clearly Superior Path for Acceleron Highlights What It Believe
5y agoMRK XLRNMerck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.Business WireMerck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that its pending acquisition of Acceleron Pharma Inc. (NASDAQ:XLRN) has been cleared by the competition authorities in Germany and Austria. As previously announced o
5y agoMRK XLRNAcceleron Reports Third Quarter 2021 Financial ResultsBusiness Wire- Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® (luspatercept-aamt) - - Three clinical abstracts on REBLOZYL have been accepted for presentation at the 63rd
5y agoBMY XLRNFarallon Capital Opposes Terms of Merck’s Acceleron TakeoverBloomberg
5y agoMRK XLRNMerck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.Business WireMerck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connecti
5y agoMRK XLRNMerck ready to quickly deploy Covid antiviral pill if it gets regulatory approval, CEO saysCNBC"We're on pace to have 10 million courses ready before the end of this year, and more than double that next year," Merck CEO Robert Davis told CNBC on Thursday.
5y agoMRK XLRNAvoro Capital Issues Open Letter to Fellow Acceleron Pharma ShareholdersBusiness WireRemains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Majo
5y agoXLRNAcceleron Announces Third Quarter 2021 REBLOZYL® Net SalesBusiness Wire- Acceleron expects to report approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – Acceleron Pharma Inc. (NASDAQ:XLRN), a bio
5y agoXLRN AUPH BMYBristol-Myers Said to Make Takeover Approach to AuriniaBloomberg
5y agoXLRN BMYBristol-Myers Said to Plan Acceleron Stake Exit With Merck DealBloomberg
5y agoMRK XLRNDarwin Global Urges Acceleron Shareholders Not to Tender Their Shares to MerckBusiness WireBelieves proposed $180/share offer price is too low and that Acceleron's share price as a standalone company will exceed offer price by at least 2-2.5x Darwin Global Management Limited ("Darwin Global"), a long-term investor in the biotechnology and
5y agoMRK XLRNHolocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues CompanyBusiness WireLong-term Holder Does Not Intend to Tender Shares into Merck's Offer Holocene Advisors, LP ("Holocene"), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. (NASDAQ:XLRN) ("Acceleron" or the "Company"), toda
5y agoMRK XLRNMerck Begins Tender Offer to Acquire Acceleron Pharma Inc.Business WireMerck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Acceleron Pharma Inc. (NASDAQ:XLRN). On Sept. 30, 2021, Merck annou
5y agoARYD NOTV TGP XLRNMoore Kuehn Encourages NOTV, ARYD, XLRN, and TGP Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
5y agoXLRN GH NEOGuardant Said to Weigh Takeover of Diagnostics Firm NeoGenomicsBloomberg
5y agoMRK XLRNAvoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron PharmaBusiness WireProposed 38% Premium Ranks Much Lower Than Average Premium of Approximately 89% for Comparable Biopharma Transactions since 2020 Believes Acceleron Has Significant Momentum Given Recent Positive Data for Sotatercept Drug Candidate Avoro Capital, a
5y agoSPCE XLRN MRK KMX+12Stocks making the biggest moves premarket: CarMax, McCormick, fuboTV, Merck and moreCNBCThese are the stocks posting the largest moves before the bell.
5y agoGILD AMGN PFE XLRNMerck to Buy Rare-Disease Specialist Acceleron for $11.5 BillionBloomberg
5y agoMRK XLRNMerck to Acquire Acceleron Pharma Inc.Business WireAcquisition Complements and Strengthens Merck's Cardiovascular Pipeline Sotatercept is a Potentially First-In-Class Therapy in Phase 3 Development for the Treatment of Pulmonary Arterial Hypertension REBLOZYL® (luspatercept-aamt) is a First-In-Cl
5y agoXLRNMerck Said to Agree to $180-Per-Share Cash Deal to Buy AcceleronBloomberg
5y agoF THO AMAT FDS+13Stocks making the biggest moves in the premarket: Ford, Thor Industries, Applied Materials and moreCNBCThe stocks making the biggest moves in premarket trading include Ford, Thor Industries, Applied Materials, and more.
5y agoXEC COG FANG MRO+15Stocks making the biggest moves midday: Best Buy, Altice, Occidental, Moderna and moreCNBCThese are the stocks posting the largest moves in midday trading.
5y agoCPE EXPE PFE TSLA+1Thinking about trading options or stock in Pfizer, Callon Petroleum, Acceleron Pharma, Tesla, or Expedia Group?PR NewswireNEW YORK, Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, CPE, XLRN, TSLA, and EXPE. C
5y agoGOOGL TSLA GGPI XLRN+6Stocks making the biggest moves in the premarket: Alphabet, Tesla, Gores Guggenheim and moreCNBCThe stocks making the biggest moves in premarket trading include Alphabet, Tesla, Gores Guggenheim, and more.
5y agoXLRNAcceleron Pharma inc (XLRN) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsXLRN earnings call for the period ending June 30, 2021.
5y agoXLRNAcceleron Announces Second Quarter 2021 REBLOZYL® Net SalesBusiness Wire- Acceleron expects to report approximately $25.6 million in royalty revenue for Q2 2021 from approximately $128 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb - Acceleron Pharma Inc. (NASDAQ:XLRN), a bioph
5y agoAGEN BLUE BMY XLRNBristol Myers Squibb Reports Second Quarter Financial Results for 2021Business WireReports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.47 and Non-GAAP EPS of $1.93 Delivers Strong Commercial Performance, Including Op
5y agoXLRNAcceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021Business WireAcceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to discuss its second quarter 2021 financial results. The webcast will be accessible under "Events & Presentat
5y agoXLRNA Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF - NCT04945460ClinicalTrials.govChange in Pulmonary Vascular Resistance (PVR) at 24 weeks from baseline, Change in 6MWD (6 minute walk distance), Number of Clinical Worsening events., (and 31 more...)
5y agoBMY XLRNBristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta ThalassemiaBusiness WireResults showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a con
5y agoXLRNAcceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021Business Wire- Event to be webcast on Tuesday, June 22 at 8:00 a.m. EDT - Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare
5y agoXLRNAcceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International ConferenceBusiness Wire– Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety prof
5y agoXLRNAcceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International ConferenceBusiness Wire- Data presented show maintained or improved responses in multiple efficacy endpoints among patients treated with sotatercept plus stable background therapy for up to 48 weeks - - Patients receiving placebo plus stable background therapy during the 2
5y agoXLRNAcceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual CongressBusiness Wire- Results from the BEYOND Phase 2 trial in non-transfusion dependent beta-thalassemia to be presented during Presidential Symposium – - Additional presentations to feature data from longer-term use of REBLOZYL in populations of patients with beta-t
5y agoXLRNAcceleron to Host Conference Call and Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) Presented at the American Thoracic Society (ATS) 2021 International ConferenceBusiness WireAcceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and web
5y agoXLRNAcceleron Reports First Quarter 2021 Financial ResultsBusiness Wire- PULSAR Phase 2 trial results published in New England Journal of Medicine - - Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society
5y agoXLRNAcceleron Pharma, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Acceleron Pharma, Inc. (NASDAQ:XLRN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 5:00 PM Eastern Time. To listen to the event live or access a
5y agoXLRNAcceleron Pharma Inc (XLRN) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsXLRN earnings call for the period ending March 31, 2021.
5y agoXLRNAcceleron Announces First Quarter 2021 REBLOZYL® Net SalesBusiness Wire- Acceleron expects to report approximately $22.4 million in royalty revenue for Q1 2021 from approximately $112 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb - Acceleron Pharma Inc. (NASDAQ:XLRN), a bioph
5y agoXLRNFDA Takes Action For Failure to Submit Required Clinical Trial Results Information to ClinicalTrials.GovFDA Press ReleasesStatement From: Statement Author Leadership Role Acting Commissioner of Food and Drugs - Food and Drug Administration Janet Woodcock M.D. Being transparent about the results of completed clinical trials enables important advances in the development of medical products and helps ensure a safe, effective and efficient clinical research enterprise. Across all types of medical product trials, the U.S. ...
5y agoXLRNAcceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021Business WireAcceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results. The webcast will be accessible under "Events & Presentations
5y agoXLRNAcceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society (ATS) 2021 International ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that updates from the PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) will be presen ...
5y agoXLRNNew England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial HypertensionBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the New England Journal of Medicine has published results of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hyper ...
5y agoC XLRN TBIO ALXNBiotech Analyst Porges Sounds Regulatory Alarm on DrugmakersBloombergBiotech analysts are usually a bullish bunch, anticipating scientific breakthroughs that will send stocks surging. But SVB Leerink’s Geoffrey Porges has broken from the pack, with cautious recommendations outweighing the number of companies he sees as buys.
5y agoXLRNA Long-term Follow-up Study of Sotatercept for PAH Treatment - NCT04796337ClinicalTrials.govFrequency of adverse events (AEs), Proportion of study participants with detectable anti-drug antibodies (ADA ), Incidence of abnormal hematology laboratory test results, (and 12 more...)